Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia

University of Louisville (UOFL)

Status and phase: Withdrawn; Phase 2

Conditions: Anemia

Treatments: Drug: Epoetin Alfa plus Iron

Study type: Interventional

Funder types: Other

Identifiers

NCT00481624

07.0210

Details and patient eligibility

About

The purpose of this study is to find a better, more convenient way to improve anemia results by increasing the amount of medication given at 3 week intervals. Researchers want to know if giving a higher dose of Procrit® and intravenous (IV) iron once every 3 weeks would give better results in treating anemia without the need for more office visits.

Full description

There are more than 170,000 patients diagnosed with lung cancer in the United States each year and many will develop anemia (iron deficiency) during the course of treatment. Anemia is associated with poor quality of life and treatment delays for advanced lung cancer. The treatment of iron deficiency anemia is with iron. Iron is an essential mineral used in red blood cells to carry oxygen throughout the body. Iron is necessary to make hemoglobin, a key element in red blood cells.

The FDA has approved Procrit® (epoetin alfa) to treat anemia in people with non-myeloid (bone marrow) malignancies. Procrit® is a man-made, injectable drug for treating anemia and it encourages red cell production. While the administration of intravenous iron therapy, injected into veins through an IV, did increase the response rate of Procrit® in a previous study, researchers want to find out the best amount of drug to use and the best time to administer Procrit®, along with ferric gluconate, (Ferrlecit®), added for lack of iron.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed small cell or non small cell lung cancer
• Stage III or Stage IV lung cancer
• Platinum containing chemotherapy induced anemia (< 10 g/dl Hb)
• Cancer related anemia (<10 g/dl Hb) at time of initiation of chemotherapy
• ECOG performance status of 0,1, or 2
• Informed consent
• Age>18
• Expected to receive platinum based outpatient chemotherapy for at least nine weeks

Exclusion criteria

• Pregnant women
• Intolerance to epoetin alfa or parenteral iron
• More than 2 cycles of the planned platinum chemotherapy at time of enrollment
• Chronic GI bleed (> than 4 weeks positive hemoccult or gastroccult)
• Ferritin > 500 mg/dl
• Anemia due to other causes than cancer or chemotherapy
• Previous parenteral iron therapy
• Uncontrolled hypertension (systolic BP > 160, diastolic > 100 mmHg)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Epoetin Alfa plus Iron

Experimental group

Treatment:

Drug: Epoetin Alfa plus Iron